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Abstract
Background: Idiopathic congenital talipes equinovarus (CTEV) is a common developmental foot disorder, the aetiology of
which remains largely unknown. Some aspects of the epidemiology suggest the possibility of aetiologically distinct
subgroups. Previous studies consider CTEV as a homogenous entity which may conceal risk factors in particular subgroups.
We investigate evidence for aetiologically distinct subgroups of CTEV.
Methods: Parents of 785 probands completed a postal questionnaire. Family pedigrees were compiled by telephone. Case-
only analysis was used to investigate interactions between risk factors and sex of the proband, CTEV laterality and CTEV
family history.
Results: The male:female ratio was 2.3:1, 58% of probands were affected bilaterally and 11% had a first-second degree
family history. There were modest interactions between family history and twin births (multivariate case - only odds ratio
[ORca] = 3.87, 95%CI 1.19–12.62) and family history and maternal use of folic acid supplements in early pregnancy
(ORca = 0.62, 95%CI 0.38–1.01); and between sex of the proband and maternal alcohol consumption during pregnancy
(female, positive history and alcohol consumed: ORca = 0.33, 95%CI 0.12–0.89). Previous reports of an interaction between
maternal smoking and family history were not confirmed. Relatives of female probands were affected more often than
relatives of male probands.
Conclusions: These results provide tentative evidence for aetiologically distinct CTEV subgroups. They support the ‘Carter
effect’, suggesting CTEV develops though a multifactorial threshold model with females requiring a higher risk factor ‘load’,
and suggest areas where future aetiological investigation might focus. Large multi-centre studies are needed to further
advance understanding of this common condition.
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Introduction
Congenital talipes equinovarus (CTEV) is a common develop-
mental disorder with birth prevalence of 1–4.5 per 1000.[1]
Affected feet are inclined inwards, axially rotated outwards, and
point downwards, with concomitant soft tissue abnormalities.[2]
Severity ranges from cases that resolve with manipulation to those
requiring multiple operations with disability and discomfort
persisting into later life. Although some cases occur with other
neuromuscular and neurological disorders, most affected children
have idiopathic CTEV.[3]
Mechanical, neurological, muscular, bony, connective tissue
and vascular mechanisms for idiopathic CTEV have all been
proposed.[3] Although genetic and lifestyle/environmental
factors are thought to be aetiologically relevant, the genetic
model is unclear and little is known about non-genetic risk
factors.[3] However, some aspects of the epidemiology suggest
areas worthy of further study: twice as many males as females are
affected[4–7] and there is evidence of the ‘Carter effect’ (higher
risk in relatives of affected females);[8,9] 7–21%[10,11] of
families report CTEV in first-degree relatives, and one study
suggests that family history modifies the association between
CTEV and maternal smoking;[10] around half of affected
children have bilateral CTEV[1,4,12,13] and mouse studies
suggest the number of affected feet is a marker for genetic
load.[14] These observations raise the possibility of aetiologically
distinct CTEV subgroups. Previous studies have considered
idiopathic CTEV as a homogenous entity that may have
concealed risk factors relevant, or more important, in particular
subgroups.
The ECCE (Exploring Causes of Clubfoot in Europe) study
comprises the largest reported series of idiopathic CTEV with
primary data collection. Here, we investigate interactions between
epidemiological risk factors and family history, the proband’s sex,
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Table 1. Study Population Characteristics by Country (part a).
Variable Categories Country Total
UK Netherlands
n (%)1 n (%)1 x2/P n (%)a
Participants Total 346 (44.1) 439 (55.9) - 785 (100)
Sex of proband Male 249 (72.0) 301 (68.6) 1.07/0.30 550 (70.1)
Female 97 (28.0) 138 (31.4) 235 (29.9)
Male:Female 2.57:1 2.18:1 2.34:1
Laterality of CTEV Left 60 (17.4) 84 (19.2) 1.39/0.41 144 (18.4)
Right 76 (20.0) 107 (24.4) 183 (23.4)
Bilateral 209 (60.6) 247 (56.4) 456 (58.2)
Unilateral 136 (39.4) 191 (43.6) 1.39/0.24 327 (41.2)
Bilateral 209 (60.6) 247 (56.4) 456 (58.2)
Year of birth (proband) 1941–1980 12 (3.5) 14 (3.2) 46.40/,0.01 26 (3.31)
1981–1990 66 (19.1) 58 (13.2) 124 (15.8)
1991–1995 126 (36.4) 97 (22.1) 223 (28.4)
1996–2000 120 (34.7) 182 (41.5) 302 (38.5)
2000–2003 22 (6.4) 88 (20.0) 110 (14.0)
Birthweight (proband, grams) ,2500 18 (5.2) 33 (7.9) 3.37/0.50 51 (6.7)
2500–2999 37 (10.1) 50 (11.9) 87 (11.4)
3000–3499 124 (35.8) 150 (35.7) 274 (35.8)
3500–3999 122 (35.3) 130 (31.0) 252 (32.9)
$4000 45 (13.0) 57 (13.6) 102 (13.3)
Gestation of pregnancy (weeks)c ,36 13 (3.8) 22 (5.1) 0.74/0.39 35 (4.5)
$36 329 (96.2) 410 (94.9) 739 (95.5)
Ethnicity of mother White 341 (98.6) 426 (97.3) 1.53/0.22 767 (97.8)
Other 5 (1.4) 12 (2.7) 17 (2.2)
Ethnicity of father White 331 (96.2) 427 (97.5) 1.04/0.31 758 (96.9)
Other 13 (3.8) 11 (2.5) 24 (3.1)
Maternal age at birth (years)c #24 28 (8.1) 22 (5.0) 6.80/0.08 50 (6.4)
25–29 116 (33.5) 129 (29.5) 245 (31.3)
30–34 138 (39.9) 210 (48.0) 348 (44.4)
35+ 64 (18.5) 77 (17.6) 141 (18.0)
Paternal age at birth (years)c #24 10 (2.9) 2 (0.5) 14.80/,0.01 11 (1.4)
25–29 73 (21.4) 76 (17.3) 149 (19.1)
30–34 127 (37.1) 208 (47.4) 335 (43.0)
35+ 132 (38.6) 152 (34.6) 284 (36.4)
Age of mother at first pregnancy (years) #24 99 (28.8) 71 (16.4) 19.63/,0.01 170 (21.9)
25–29 160 (46.5) 220 (50.7) 380 (48.8)
30–34 73 (21.2) 129 (29.7) 202 (26.0)
35+ 12 (3.5) 14 (3.2) 33 (3.3)
Rank of index pregnancy 1 144 (41.6) 214 (48.8) 4.30/0.12 358 (45.6)
2 122 (35.3) 142 (32.4) 264 (33.6)
3+ 80 (23.1) 83 (18.9) 163 (20.7)
Total pregnancies (including index) 1 48 (13.9) 75 (17.1) 1.70/0.43 123 (15.7)
2 140 (40.5) 177 (40.3) 317 (40.4)
3+ 158 (45.7) 187 (42.6) 345 (44.0)
Previous miscarriage Yes 99 (28.7) 127 (28.9) 0.01/0.93 226 (28.9)
No 246 (71.3) 311 (71.0) 557 (71.1)
Previous stillbirth Yes 5 (1.5) 8 (1.8) 0.17/0.68 13 (1.7)
No 341 (98.6) 430 (98.2) 771 (98.3)
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and laterality of the condition. We also report family pedigree
analyses.
Methods
Ethics Statement
The Grampian Research Ethics Committee approved the study
and written consent was obtained from each participating family
(most often the mother signed on behalf of her partner and
participating children).
Subjects
Subjects were recruited May 2001–May 2003 through
two support groups, steps[15] in the United Kingdom and
VOK[16] in the Netherlands. The support groups approached
families by mail on behalf of the investigators. A parent of the
affected child (generally the mother) completed a questionnaire
that included: nature of the condition (laterality, treatment, other
medical conditions), maternal reproductive history, parental
lifestyle (tobacco, alcohol, folic acid supplement and oral
contraceptive [OC] use in the periconceptional period of the
index pregnancy), and CTEV family history. On questionnaire
receipt, a clinical geneticist (ZM) reviewed details of the foot
defect and any additional conditions to exclude syndromic cases
and non-CTEV conditions. Pedigrees were elicited by telephone
from families who reported CTEV in family members other than
the proband.
Statistical analysis
The analysis included unrelated index children with idiopathic
CTEV. Case-only methods[17,18] were used to investigate
whether CTEV risk factors differed by presence/absence of
CTEV family history; sex of the proband; or laterality of the
condition. Analysis contrasted sub-groups of cases with particular
combinations of these ‘‘stratification variables’’ and risk factor
exposures (e.g. male/female proband and maternal folic acid
use/non-use), with the ‘‘association’’ between the stratification
variable and risk factor (strictly the interaction, or departure from
a multiplicative relationship) expressed as a case-only odds ratio
(ORca). The stratification variables reference categories were: no
family history; male; and unilateral CTEV. The primary analysis
concerned first or second-degree family history. Using logistic
regression, a ‘‘minimally adjusted’’ ORca was computed for each
risk factor adjusted for country. Factors where the likelihood ratio
test (LRT) p value was #0.1 in minimally adjusted analysis were
considered for inclusion in multivariate models. Final multivar-
iate models included country and variables where p#0.1 for the
LRT comparing the multivariate model containing the variable
with the model that did not. The family history analysis was
repeated stratifying by sex, since sex differences have been
reported.[10]
Using the pedigrees, the total numbers of affected and
unaffected first and second- degree relatives were determined.
The ratio of affected to total relatives was calculated overall and by
sex of the relative, proband, and relative and proband.
Associations were assessed using the chi-square test.
Results
Of 1504 invited families, 827 completed questionnaires
(participation rate = 55%). 42 families were excluded because the
foot condition was not idiopathic CTEV. This analysis includes
785 probands.
Participant characteristics
The male:female ratio was 2.3:1 (Tables 1, 2). More than half
had bilateral CTEV (58%). In unilateral cases the right foot was
affected most often (56% right, 44% left). CTEV in first-second
degree family members was reported by 11% of families, in first-
third degree relatives by 16% and in ‘any’ family member by 26%.
Family history associations
Factors that interacted with first-second degree family history in
relation to CTEV risk were: maternal OC use, maternal use of
folic acid-containing supplements, maternal ethnicity, twin birth
and birthweight (Tables 3, 4, 5). Compared to those with no family
history, probands with a family history were more likely to have a
twin, have mothers who were non-Caucasian, and have mothers
who took OCs in early pregnancy; they were less likely to have
mothers who took folic acid supplements periconceptionally.
Maternal smoking in the periconceptional period was less
common in those with a family history, reflected in an inverse, but
non-statistically significant, ORca (multivariate ORca= 0.64,
95%CI 0.34–1.22, p = 0.16). The risk estimates were similar for
smoking in the three months pre-conception and in the first
trimester (data not shown). There was no association with paternal
smoking.
After stratifying by sex, males with a family history were more
likely than those without to have mothers who took OCs in early
pregnancy (multivariate ORca=4.35, 95%CI 1.01–18.78,
p = 0.07) and to have a twin (ORca= 5.28, 95%CI 1.31–21.32,
p= 0.03), and less likely to have mothers who took folic acid-
containing supplements first trimester (ORca= 0.59, 95%CI 0.31–
1.10, p= 0.10) or who had previously had a miscarriage
Variable Categories Country Total
UK Netherlands
n (%)1 n (%)1 x2/P n (%)a
Periconceptional folic acid supplementsb,c Yes 195 (56.7) 227 (51.8) 1.83/0.18 422 (54.0)
No 149 (43.3) 211 (48.2) 360 (46.0)
Oral contraceptives early pregnancyb,c Yes 12 (3.9) 3 (0.7) 9.22/,0.01 15 (2.0)
aPercentages may not total 100 because of rounding.
bMaternal use/condition.
cindex pregnancy.
doi:10.1371/journal.pone.0017895.t001
Table 1. Cont.
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(ORca=0.53, 95%CI 0.24–1.17, p= 0.10). Birthweight distribu-
tion varied between males with and without a family history
(,2500 g ORca= 0.66 95%CI 0.15–2.89; 2500–2999 g OR-
ca= 1.12, 95%CI 0.42–2.99; 3000–3499 g ORca=1.00 [refer-
ence]; 3500–3999 g ORca= 0.43, 95%CI 0.18–1.03; $4000 g
ORca= 1.57 95%CI 0.70–3.55; p= 0.07). Females with a family
history were less likely than those without to have been delivered
by caesarean section (ORca= 0.23, 95%CI 0.03–1.86, p= 0.10)
and to have mothers who consumed alcohol (ORca=0.33, 95%CI
0.12–0.89, p= 0.02) or had an infection (ORca= 0.11, 95%CI
0.01–0.95, p= 0.01) during pregnancy. They were more likely to
have mothers who were non-Caucasian (ORca= 16.18, 95%CI
1.19–220.5, p= 0.03) and who had an amniocentesis in the index
pregnancy (ORca=5.69, 95%CI 1.46–22.15, p= 0.02).
Associations by proband sex
The factors which interacted with sex to affect CTEV risk were:
maternal gravidity and miscarriage history, chorionic villus
sampling in the index pregnancy, forceps delivery, birthweight,
and proband birth year. Compared to males, females were more
Table 2. Study Population Characteristics by Country (part b).
Variable Categories Country Total
UK Netherlands
n (%)1 n (%)1 x2/P n (%)a
No 298 (96.1) 430 (99.3)
Periconceptional tobacco usebc Yes 64 (18.6) 107 (24.4) 3.84/0.05 171 (21.8)
No 281 (81.5) 332 (75.6)
Paternal periconceptional tobacco usec Yes 95 (27.7) 129 (29.5) 0.31/0.58 224 (28.7)
No 248 (72.3) 308 (70.5)
Alcoholbc Yes 177 (51.3) 131 (29.9) 37.02/,0.01 308 (39.3)
No 168 (48.7) 307 (70.1)
Maternal diabetesc Yes 4 (1.2) 10 (2.3) 1.39/0.24 14 (1.8)
No 342 (98.8) 429 (97.7) 771 (98.2)
Maternal epilepsyc Yes 3 (0.9) 3 (0.7) 0.08/0.77 6 (0.8)
No 343 (99.1) 435 (99.3) 778 (99.2)
Maternal infection (any)c Yes 42 (13.1) 51 (11.6) 0.37/0.54 93 (12.2)
No 279 (86.9) 388 (88.4) 667 (87.8)
Pre-eclampsiac Yes 19 (5.5) 28 (6.4) 0.27/0.60 47 (6.0)
No 325 (94.5) 408 (93.6) 733 (94.0)
Amniocentesisc Yes 40 (11.7) 19 (4.3) 15.04/,0.01 59 (7.6)
No 301 (88.3) 420 (95.7) 721 (92.4)
Chorionic villus samplingc Yes 3 (0.9) 7 (1.6) 0.72/0.40 10 (1.3)
No 330 (99.1) 431 (98.4) 761 (98.7)
Birth presentation (proband) Cephalic 323 (94.7) 418 (96.3) 1.15/0.28 741 (95.6)
Breech 18 (5.3) 16 (3.7) 34 (4.4)
Forceps deliveryc Yes 39 (11.3) 12 (2.7) 23.25/,0.01 51 (6.5)
No 306 (88.7) 426 (97.3)
Suction deliveryc Yes 27 (7.8) 44 (10.1) 1.15/0.28 71 (9.1)
No 318 (92.2) 394 (90.0)
Caesarean deliveryc Yes 56 (16.2) 38 (8.7) 10.43/,0.01 94 (12.0)
No 289 (83.8) 400 (91.3)
Multiple birthc Twinc 7 (2.0) 16 (3.6) 1.79/0.18 23 (2.9)
Singletonc 339 (98.0) 423 (96.4) 762 (97.1)
1st–2nd degree family history of CTEV Yes 37 (10.7) 45 (10.3) 0.04/0.84 82 (10.5)
No 309 (89.3) 394 (89.8) 703 (89.6)
1st–3rd degree family history of CTEV Yes 55 (15.9) 72 (16.4) 0.04/0.85 127 (16.2)
No 291 (84.1) 367 (83.6) 658 (83.8)
Any family history of CTEV Yes 77 (22.3) 123 (28.0) 3.39/0.07 200 (25.5)
No 269 (77.8) 316 (72.0) 585 (74.5)
aPercentages may not total 100 because of rounding.
bMaternal use/condition.
cindex pregnancy.
doi:10.1371/journal.pone.0017895.t002
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likely to have mothers who were multiparous (two pregnancies:
multivariate ORca=2.46, 95%CI 1.40–4.30; $three pregnancies:
ORca= 1.98, 95%CI 1.08–3.66, p= 0.005), had a history of
miscarriage (ORca=1.42, 95%CI 0.94–2.12, p= 0.09), and had
chorionic villus sampling in the index pregnancy (ORca= 3.27,
95%CI 0.90–11.90, p= 0.07). Females were less likely to have
been delivered by forceps (ORca= 0.31, 95%CI 0.13–0.77,
p= 0.01), were lighter at birth and were more likely to be born
in earlier years (data not shown).
Associations by CTEV laterality
The factors which interacted with laterality to affect CTEV risk
were: gestation, maternal gravidity and alcohol consumption, and
family history. Compared to unilateral CTEV, probands affected
bilaterally were less likely to have been premature (multivariate
ORca= 0.51, 95%CI 0.24–1.09, p= 0.07) and to have mothers
who consumed alcohol during pregnancy (ORca= 0.76, 95%CI
0.56–1.03, p= 0.07), but more likely to have a first- third degree
family history (ORca=1.43, 95%CI 0.95–2.14, p= 0.08) and to
have mothers who had two pregnancies in total (one pregnancy
ORca 1.00 [reference], two pregnancies ORca= 1.38, 95%CI
0.89–2.12; $three pregnancies ORca= 0.90, 95%CI 0.59–1.39;
p= 0.03).
Pedigree analysis
CTEV in first-degree relatives was reported in 5.7% (45/785) of
families; 5.7% (45/785) had affected second-degree relatives, 1.0%
(8/785) had affected first and second-degree relatives and 10.5%
(82/785) had affected first or second-degree relatives. Of those with
a first-degree family history, 38 had one affected relative (15 sibs,
14 fathers, nine mothers), six had two affected relatives (three sib/
mother-pairs, one sib/father-pair and two sib-pairs) and one had
three affected relatives (mother and two sibs). Regardless of degree
of relatedness, 139 families reported one affected relative, 46
Table 3. Association Between Epidemiological Variables and 1st–2nd Degree Family History (part a).
1st–2nd degree family history Minimally adjusted
a
LRT Multivariateb LRT
Yes No
Variable Categories n (%) n (%) ORca 95% CIs x2/P ORca 95% CIs x2/P
Participants Total 82 (10.4) 703 (89.6)
Country UK 37 (45.1) 309 (43.9) 1.00 reference 0.04/0.84 1.00 reference 0.19/0.66
Netherlands 45 (54.9) 394 (56.1) 0.95 [0.60, 1.51] 0.90 [0.55, 1.47]
Sex Male 51 (62.2) 499 (71.0) 1.00 2.57/0.25 1.00 reference 2.29/0.13
Female 31 (37.8) 204 (29.0) 1.49 [0.93, 2.40] 1.49 [0.90, 2.48]
Male:female 1.65:1 2.45:1 - - - -
Laterality of CTEV Left 15 (18.3) 129 (18.4) 1.00 reference 3.33/1.90 1.00 reference 2.68/0.26
Right 13 (15.9) 170 (24.3) 0.66 [0.30, 1.43] 0.70 [0.31, 1.59]
Bilateral 54 (65.9) 402 (57.4) 1.15 [0.63, 0.21] 1.19 [0.61, 2.29]
Unilateral 28 (34.2) 299 (42.7) 1.00 reference 2.21/0.14 1.00 reference 1.97/0.16
Bilateral 54 (65.9) 402 (57.4) 1.43 [0.89, 2.32] 1.43 [0.86, 2.39]
Year of birth (proband) 1941–1980 5 (6.1) 21 (3.0) 2.43 [0.85,6.95] 4.82/0.44 2.07 [0.60,7.17] 2.33/0.68
1981–1990 18 (22.0) 106 (15.1) 1.73 [0.91,3.28] 1.60 [0.75,3.40]
1991–1995 22 (26.9) 201 (28.6) 1.12 [0.61,2.03] 1.11 [0.56,2.19]
1996–2000 27 (32.9) 275 (39.1) 1.00 reference 1.00 reference
2000–2003 10 (12.2) 100 (14.2) 1.02 [0.47,2.19] 1.16 [0.52,2.60]
Birthweight (proband, grams) ,2500 7 (8.9) 44 (6.4) 1.53 [0.63, 3.76] 9.06/0.06 1.20 [0.50, 3.14] 8.95/0.06
2500–2999 10 (12.7) 77 (11.2) 1.24 [0.57, 2.69] 1.19 [0.55, 2.59]
3000–3499 26 (32.9) 248 (36.1) 1.00 reference 1.00 reference
3500–3999 18 (22.8) 234 (34.1) 0.73 [0.39, 1.37] 0.58 [0.30, 1.12]
$4000 18 (22.8) 84 (12.2) 2.05 [1.07, 3.92] 1.70 [0.87, 3.32]
Gestation of pregnancy (weeks)c ,36 5 (6.3) 30 (4.3) 1.00 reference 0.57/0.45 1.00 reference 0.53/0.47
$36 75 (93.8) 664 (95.7) 0.68 [0.25, 1.80] 0.64 [0.19, 2.10]
Ethnicity of mother White 78 (95.1) 689 (98.2) 1.00 reference 2.50/0.11 1.00 reference 4.02/0.05
Other 4 (4.9) 13 (1.9) 2.74 [0.87, 8.66] 3.94 [1.17, 13.32]
Ethnicity of father White 78 (96.3) 680 (97.0) 1.00 reference 0.11/0.74 1.00 reference 0.22/0.64
Other 3 (3.7) 21 (3.0) 1.24 [0.36, 4.24] 1.37 [0.38, 4.86]
Abbreviations:CI, confidence interval; ORca, Case-only odds ratio; LRT, likelihood ratio test.
aAdjusted for centre.
bAdjusted for centre, birthweight, maternal use of supplements containing folic acid (during the three months before the pregnancy or during the first trimester), and
use of oral contraceptives when the mother recognised the pregnancy.
cIndex pregnancy.
doi:10.1371/journal.pone.0017895.t003
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reported two, 13 reported three, two reported four and five
reported five.
CTEV risk to any first-degree relative was 2.2% and to any first
or second-degree relative 1.2% (Table 6). Male relatives were
affected more often than female relatives (first-second degree 1.4%
vs 1.0%, p= 0.05. Table 7) and relatives of female probands were
affected more often than relatives of male probands (first-second
degree 1.6% vs 1.0%, p= 0.01, Table 8). Male relatives of female
probands had the highest absolute risk (first-second degree 2.0%,
p= 0.02, Table 9).
Discussion
Strengths and limitations
Most previous CTEV studies have either been based on routine
data, which gives large sample sizes but lack certainty about the
diagnosis of CTEV, or on small clinical series from single centres,
which may be highly selected. In addition, studies do not always
distinguish clearly between syndromic and idiopathic CTEV. The
current study is the largest reported series of idiopathic CTEV
involving primary data collection, and we carefully reviewed
questionnaires to exclude syndromic CTEV and other foot
conditions. The case-only design is statistically powerful for the
investigation of interactions.[17,18] The key assumption under-
pinning the design is independence in the population between the
stratification variable and risk factor;[19] if violated, risk estimates
may be biased. We are not aware of any evidence to suggest the
factors considered are not independent.
Recall accuracy and diagnostic reliability are challenges in
family history analyses. We confirmed positive reports by
telephone interview and additional questionnaires where possible,
and restricted most analyses to first-second degree history, which
may be more accurately reported.
Study participants were accrued from two national support
groups, raising the possibility that they might not be representative
of all idiopathic CTEV. For the results to be seriously biased, the
Table 4. Association Between Epidemiological Variables and 1st–2nd Degree Family History part b).
1st–2nd degree family history Minimally adjusted
a
LRT Multivariateb LRT
Yes No
Variable Categories n (%) n (%) ORca 95% CIs x2/P ORca 95% CIs x2/P
Maternal age at birth (years)c #24 8 (9.8) 42 (6.0) 1.00 reference 2.58/0.46 1.00 reference 0.51/0.92
25–29 28 (34.2) 217 (30.9) 0.68 [0.29, 1.59] 0.82 [0.30–2.23]
30–34 31 (37.8) 317 (45.2) 0.51 [0.22, 1.20] 0.73 [0.27–1.98]
35+ 15 (18.3) 126 (18.0) 0.63 [0.25, 1.58] 0.86 [0.30–2.52]
Paternal age at birth (years)c #24 2 (2.5) 10 (1.4) 1.00 reference 1.07/0.79 1.00 reference 0.87/0.83
25–29 18 (22.2) 131 (18.7) 0.70 [0.14, 3.48] 0.58 [0.11, 3.11]
30–34 32 (39.5) 303 (43.4) 0.54 [0.11, 2.61] 0.53 [0.10, 2.75]
35+ 29 (35.8) 255 (36.5) 0.58 [0.12, 2.80] 0.64 [0.12, 3.36]
Age of mother at first pregnancy (years) #24 21 (25.6) 149 (21.2) 1.00 reference 0.91/0.92 1.00 reference 0.20/0.98
25–29 37 (45.1) 343 (48.8) 0.77 [0.43, 1.36] 0.99 [0.52, 1.90]
30–34 21 (25.6) 181 (25.8) 0.83 [0.43, 1.59] 1.13 [0.54, 2.35]
35+ 3 (3.7) 30 (4.3) 0.71 [0.20, 2.54] 1.06 [0.28, 3.99]
Rank of index pregnancy 1 44 (53.7) 314 (44.7) 1.00 reference 2.51/0.47 1.00 reference 3.64/0.16
2 23 (28.1) 241 (34.3) 0.68 [0.40, 1.16] 0.60 [0.33, 1.07]
3+ 15 (18.3) 148 (21.0) 0.72 [0.39, 1.34] 0.65 [0.33, 1.27]
Total pregnancies (including proband) 1 10 (12.2) 113 (16.1) 1.00 reference 1.29/0.73 1.00 reference 1.41/0.49
2 32 (39.0) 285 (40.5) 1.27 [0.60, 2.66] 1.55 [0.69, 3.48]
3+ 40 (48.8) 305 (43.4) 1.48 [0.72, 3.06] 1.56 [0.71, 3.45]
Previous miscarriage Yes 23 (28.1) 203 (29.0) 0.96 [0.58, 1.59] 0.03/0.86 0.85 [0.47, 1.46] 0.37/0.54
No 59 (72.0) 498 (71.0) 1.00 reference 1.00 reference
Previous stillbirth Yes 0 (0.0) 13 (1.9) - - - - - -
No 82 (100.0) 689 (98.2) - - - - -
Periconceptional folic acid supplementscd Yes 36 (43.9) 386 (55.0) 0.64 0.40, 1.01] 3.77/0.05 0.62 [0.38, 1.01] 3.71/0.05
No 46 (56.1) 314 (44.9) 1.00 reference 1.00 reference
Oral contraceptives early pregnancycd Yes 4 (5.1) 11 (1.7) 3.17 [0.97, 10.38] 3.05/0.08 3.21 [0.94, 10.99] 2.94/0.09
No 74 (94.9) 654 (98.4) 1.00 reference 1.00 reference
Abbreviations:CI, confidence interval; ORca, Case-only odds ratio; LRT, likelihood ratio test.
aAdjusted for centre.
bAdjusted for centre, birthweight, maternal use of supplements containing folic acid (during the three months before the pregnancy or during the first trimester), and
use of oral contraceptives when the mother recognised the pregnancy.
cIndex pregnancy.
dmaternal use.
doi:10.1371/journal.pone.0017895.t004
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(
probability of participation would need to have been asso-
ciated with family history, laterality or proband sex. The sex ratio
and laterality distribution mirrors patterns seen else-
where.[1,4,6,11,20–27] Moreover, the proportion with a family
history corresponds with the upper limit of estimates from two US
series,[4,28] is consistent with the UK Talipes series,[26] and is
slightly lower that in series of 120 Scottish children.[22] This
suggests our results are unlikely to be seriously biased.
Parental smoking
Reports of associations between foot deformities, including
CTEV, and maternal smoking during pregnancy are inconsis-
tent.[5,7,10,29–33] One US case-control study of idiopathic
CTEV reported a greater than multiplicative interaction between
smoking and family history, such that maternal smoking increased
risk only in children with a family history (OR 20.30, 95%CI
7.90–52.17).[10] We, in contrast, found no evidence of any
interaction between family history and maternal (or paternal)
smoking in the three months before, or first trimester of, the index
Table 5. Association Between Epidemiological Variables and 1st–2nd Degree Family History (part c).
1st–2nd degree family history Minimally adjusted
a
LRT Multivariateb LRT
Yes No
Variable Categories n (%) n (%) ORca 95% CIs x2/P ORca 95% CIs x2/P
Periconceptional tobacco usecd Yes 14 (17.1) 157 (22.4) 0.72 [0.39, 1.31] 1.24/0.27 0.64 [0.34, 1.22] 2.00/0.16
No 68 (82.9) 545 (77.6) 1.00 reference 1.00 reference
Paternal periconceptional tobacco usec Yes 22 (27.5) 202 (28.9) 0.94 [0.56, 1.57] 0.06/0.80 0.81 [0.46, 1.43] 0.52/0.47
No 58 (72.5) 498 (71.1) 1.00 reference 1.00 reference
Alcoholcd Yes 24 (29.3) 284 (40.5) 0.59 [0.35, 0.98] 4.41/0.04 0.68 [0.40, 1.16] 2.07/0.15
No 58 (70.7) 417 (59.5) 1.00 reference 1.00 reference
Maternal diabetesc Yes 1 (1.2) 13 (1.9) 0.66 [0.09, 5.12] 0.18/0.67 - - -
No 81 (98.8) 690 (98.2) 1.00 reference - -
Maternal epilepsyc Yes 0 (0.0) 6 (0.9) - - - - - -
No 82 (100.0) 696 (99.2) - - - -
Maternal infection (any)c Yes 6 (7.6) 87 (12.8) 0.56 [0.24, 1.33] 1.99/0.16 0.53 [0.21, 1.37] 2.01/0.16
No 73 (92.4) 594 (87.2) 1.00 reference 1.00 reference
Pre-eclampsiac Yes 6 (7.4) 41 (5.9) 1.29 [0.53, 3.13] 0.29/0.59 1.45 [0.57, 3.64] 0.57/0.45
No 75 (92.6) 658 (94.1) 1.00 reference 1.00 reference
Amniocentesisc Yes 9 (11.0) 50 (7.2) 1.59 [0.74, 3.39] 1.31/0.25 1.96 [0.89, 4.30] 2.50/0.11
No 73 (89.0) 648 (92.8) 1.00 reference 1.00 reference
Chorionic villus samplingc Yes 0 (0.0) 10 (1.5) - - - -
No 81 (100.0) 680 (98.6) - - - -
Birth presentation (proband) Breech 2 (2.5) 32 (4.6) 0.53 [0.12, 2.25] 0.89/0.35 0.56 [0.13, 2.40] 0.72/0.40
Cephalic 78 (97.5) 663 (95.4) 1.00 reference 1.00 reference
Forceps deliveryc Yes 8 (9.8) 43 (6.1) 1.66 [0.74, 3.72] 1.37/0.24 1.34 [0.55, 3.27] 0.40/0.53
No 74 (90.2) 658 (93.9) 1.00 reference 1.00 reference
Suction deliveryc Yes 7 (8.5) 64 (9.1) 0.93 [0.41, 2.11] 0.03/0.86 1.09 [0.47, 2.54] 0.04/0.84
No 75 (91.5) 637 (90.9) 1.00 reference 1.00 reference
Caesarean deliveryc Yes 7 (8.5) 87 (12.4) 0.65 [0.29, 1.46] 1.20/0.27 0.75 [0.33, 1.71] 0.50/0.48
No 75 (91.5) 614 (87.6) 1.00 reference 1.00 reference
Multiple birthc Twin 5 (6.1) 18 (2.6) 2.50 [0.90, 6.93] 2.61/0.11 3.87 [1.19, 12.62] 4.37/0.04
Singleton 77 (93.9) 685 (97.4) 1.00 reference 1.00 reference
Abbreviations:CI, confidence interval; ORca, Case-only odds ratio; LRT, likelihood ratio test.
aAdjusted for centre.
bAdjusted for centre, birthweight, maternal use of supplements containing folic acid (during the three months before the pregnancy or during the first trimester), and
use of oral contraceptives when the mother recognised the pregnancy.
cIndex pregnancy.
dmaternal use.
doi:10.1371/journal.pone.0017895.t005
Table 6. Overall Risk of CTEV in 1st and 2nd Degree Relatives
of Probands.
Relation degree
No. relatives/total
relatives (%) 95% CI
1st degree 53/2388 (2.2) 1.67, 2.89
1st–2nd degree 106/9087(1.2) 0.96, 1.41
Abbreviations: CI, confidence interval.
doi:10.1371/journal.pone.0017895.t006
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pregnancy. If anything our risk estimates suggested a less than
multiplicative interaction, although they were not statistically
significant.
In our study maternal smoking prevalence in the first trimester
was 15% (22% in the three months before the pregnancy or first
trimester) compared with 38% in the first trimester among cases
in the US study. This difference could be due to differences in
data collection methods (interview versus postal questionnaire),
study location or subjects’ period of birth (1968–1980 vs 1941–
2003 [.70% 1991–2000]). The US study defined family history
as ‘probable’ CTEV in first-degree relatives, but when we
restricted our analysis to first-degree relatives and first trimester
smoking the risk estimate was further from unity (multivariate
ORca= 0.59, 95%CI 0.21–1.69, p = 0.30). The CTEV-smoking
relationship, in those with or without a family history, thus
remains controversial, and a role for smoking in CTEV cannot be
entirely ruled out.
Perinatal factors and other maternal exposures during
index pregnancy
The observed significant (p = 0.04) interaction between a
positive family history and twin births is novel and may have
become evident because, unlike previous studies of CTEV and
twinning,[4,34] we stratified by family history. It could be
interpreted as consistent with the uterine constraint hypothesis
for CTEV.[3]
As with other congenital anomalies,[35] there is some evidence
of a role for folate metabolism in CTEV.[13,36,37] The
borderline significant interaction between family history and
maternal folic acid supplement use (p = 0.09) provides some
further support for this. Although recall accuracy might be a
concern, it seems unlikely this would be differential by family
history. Since our results suggest supplement use might be
associated with reduced CTEV risk in those without a family
history further investigation is warranted.
Although observed in a subgroup analysis, the significant
interaction (p = 0.02) between maternal alcohol consumption and
family history in females is intriguing (mothers of female
probands with a family history were less likely to report
alcohol consumption). It is unlikely the finding reflects avoi-
dance of ‘risky’ behaviour during pregnancy in women aware of
a family history, as the association was not seen in males.
Although alcohol is teratogenic,[38] it has rarely been con-
sidered in relation to CTEV and further investigation would be
valuable.
The suggestion of an interaction between family history and
maternal OC use in early pregnancy is of interest, especially as the
effect was strongest in males. Increased risk of congenital limb
deficiencies in offspring of mothers who had taken relatively high-
dose OCs in the periconceptional period has been reported,[39]
suggesting our finding could be due to specific OC types (e.g.
higher-dose or anti-androgenic OCs). We could not explore
further as we did not have information on types of OCs used.
However, while some studies report modest increased risks of birth
defects, including limb deformities, with OC use,[40] the FDA
concluded they were not teratogenic[41] and it is unclear how
much of the maternal hormones reach the fetus and whether
exogenous hormones are more likely to cross the placental barrier
than endogenous (P Fowler, personal communication). Moreover,
since our result was only borderline significant it may be due to
chance.
Carter effect
Our results add to growing evidence for the Carter effect and a
multifactorial threshold model in CTEV. The observed higher
CTEV risk in relatives of female probands is consistent both with
early work from Wynne-Davis et al, based on 144 UK cases born
in 1940–1961,[8] and a recent US study which described
increased CTEV transmission from mothers to their offspring
compared with fathers.[9] Although other studies found CTEV
risk was independent of the proband’s sex, these included relatively
few pedigrees (n,175).[4,26] The somewhat different risk factor
pattern in females and males also points towards the possibility
that a higher ‘‘load’’ of risk factors (whether genetic and/or
environmental) in families of affected girls might predispose to
CTEV.
Table 7. Risk of CTEV in 1st and 2nd Degree Relatives of Probands by the Sex of the Relative.
Relation degree Sex of relative No. relatives/total relatives (%) 95% CI x2/P
1st degree Female 23/1189 (1.9) 1.23, 2.89 0.72/0.40
Male 29/1187 (2.4) 1.64, 3.49
1st–2nd degree Female 42/4498 (1.0) 0.67, 1.26 3.88/0.05
Male 63/4578 (1.4) 1.11, 1.76
Abbreviations: CI, confidence interval.
doi:10.1371/journal.pone.0017895.t007
Table 8. Risk of CTEV in 1st and 2nd Degree Relatives of Probands by the Sex of the Proband.
Relation degree Sex of proband No. relatives/total relatives (%) 95% CI x2/P
1st degree Female 22/719 (3.1) 1.93, 4.60 3.35/0.07
Male 31/1669 (1.9) 1.27, 2.62
1st–2nd degree Female 46/2811 (1.6) 1.20, 2.18 7.80/0.01
Male 60/6276 (1.0) 0.73, 1.23
Abbreviations: CI, confidence interval.
doi:10.1371/journal.pone.0017895.t008
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Conclusions
Using the largest series of idiopathic CTEV with primary data
collection so far reported, we set out to (1) follow-up previous
observations suggesting the possibility of risk factor heterogeneity
and (2) generate hypotheses for future study. Our results provide
support for the ‘Carter effect’, suggesting that females require a
higher risk factor ‘load’ before developing CTEV. Beyond this,
although we found only tentative evidence for aetiologically
distinct subgroups, our results do suggest some areas worth further
exploration, including the relationships between family history and
twinning and maternal use of folic acid supplements and alcohol
during the index pregnancy. Large multi-centre studies, with
sufficient power to fully explore risk factors in different case sub-
groups, are needed to further elucidate the aetiology of this
common, but poorly understood, condition.
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